<DOC>
	<DOCNO>NCT00295841</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine clofarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I trial study side effect best dose clofarabine give together cytarabine see well work treat patient refractory relapse acute myeloid leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Cytarabine Clofarabine Treating Patients With Refractory Relapsed Acute Myeloid Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate adult patient relapse refractory acute myeloid leukemia acute lymphoblastic leukemia treat high-dose cytarabine follow clofarabine . - Document safety profile tolerability regimen patient . - Phase I : Patients receive high-dose cytarabine IV 3 hour follow clofarabine IV 2 hour day 1-5 . Treatment repeat 4 course ( 1-2 induction course , 2-3 post-remission course ) absence disease progression unacceptable toxicity . A cohort 3-6 patient receive start dose clofarabine . If 1 6 patient experience dose-limiting toxicity ( DLT ) , subsequent cohort patient receive clofarabine next high dose . If ≥ 2 6 patient experience DLT , dose cytarabine reduce subsequent cohort patient receive cytarabine reduce dos clofarabine per dose-escalation scheme . PROJECTED ACCRUAL : A total 9 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologic confirmation acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) No M3 AML Meets 1 follow criterion : In first relapse In second relapse second complete remission ( CR ) last ≥ 3 month Refractory initial induction therapy No symptomatic CNS involvement PATIENT CHARACTERISTICS : ECOG performance status ≤ 2 Creatinine &lt; 2 mg/dL Bilirubin ≤ 2 mg/dL AST ALT ≤ 4 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week complete study treatment Ejection fraction ≥ 45 % echocardiogram No active , uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant No psychiatric disorder would interfere give consent , study participation , followup procedures No severe concurrent disease would preclude study treatment PRIOR CONCURRENT THERAPY : At least 1 week since prior therapy recover No concurrent chemotherapy Hydroxyurea control WBC count start study treatment allow No concurrent corticosteroids unless use disease leukemia No concurrent palliative radiotherapy No concurrent growth factor ( e.g. , epoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] ) patient AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>